|Novo Nordisk||Vice President||Denmark|
What are the outcomes of long-lasting commitment between universities and pharmaceutical companies?
Ulrik Lytt Rahbek is since 2016 Vice President in Global Research at Novo Nordisk. Ulrik joined Novo Nordisk in 2009 as a Research Scientist.
Ulrik is currently responsible for the Assay, Analysis & Characterisation function where the characterisation and selection of the optimal drug molecules for use across Novo Nordisk’s therapy areas is carried out. This currently includes a wide variety of diverse molecular formats within diabetes, obesity, NASH, CVD and haemophilia.
In addition, his activities at Novo Nordisk have included holding responsibility for global innovation scouting and evaluation of novel technologies and drug delivery systems through which he has been initiating and driving collaborations with both academia and biotech. Ulrik is currently heading up the successful Novo Nordisk research collaboration with the Langer Laboratory at MIT; a truly innovative and interdisciplinary project focused on the development of novel devices for the oral administration of macromolecular drugs.
Ulrik has an in-depth understanding of the pharmaceutical research & development value chain from early target discovery and validation to handover to CMC and clinical development through more than 15 years of experience from academia, biotech and big pharma.